In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

These two processes remodel the tumor cell environment in melanoma through the RAF/MEK cell signaling pathway. However, the combined use of FAK inhibitors with a RAF-MEK clamp overcame this resistance ...

Melanoma is the deadliest form of skin cancer ... "There is an emerging class of drugs known as second generation RAF inibitors. Unlike BRAF inhibitors, these drugs have a broad spectrum, and ...

The lab utilizes melanoma as a model system to investigate the following ... and how they can be leveraged as diagnostic features or exploited to improve tumor immune response. Mutations in the ...

Immuneering has dosed the first subject in its Phase I/IIa clinical trial of IMM-6-415 for the treatment of advanced solid tumours with specific genetic mutations. A Deep Cyclic Inhibitor (DCI) of ...